Lonza to Buy U.S. Manufacturing Facility From Roche For $1.2 Billion
By Andrea Figueras
Lonza agreed to buy a manufacturing facility in the U.S. from Roche for around $1.2 billion in cash as it seeks to boost growth of its biologics division.
The deal, due to close in the second half subject to customary conditions, is expected to increase sales growth, the Swiss life-sciences company said Wednesday, raising its mid-term target for 2024-28.
Lonza now estimates a compound annual sales growth rate between 12% and 15% at constant currency, while it previously anticipated it in a range of 11% to 13%.
The rest of its guidance remains unchanged.
Lonza plans to invest around CHF500 million to upgrade the Genentech facility in Vacaville, Calif., one of the largest biologics manufacturing sites in the world by volume.
Roche's products currently manufactured at the site will be supplied by Lonza, with committed volumes over the medium term, phasing out over time, Lonza said.
As part of the agreement, Lonza will offer employment to some 750 Genentech workers at the U.S. facility.
The deal is expected to boost the company's large-scale biologics manufacturing capacity, helping it meet demand for commercial mammalian contract manufacturing from customers with existing commercial products, and molecules currently on the path to commercialization, it said.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
March 20, 2024 02:59 ET (06:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks